1. Home
  2. PWUP vs ASMB Comparison

PWUP vs ASMB Comparison

Compare PWUP & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PWUP
  • ASMB
  • Stock Information
  • Founded
  • PWUP 2021
  • ASMB 2005
  • Country
  • PWUP United States
  • ASMB United States
  • Employees
  • PWUP N/A
  • ASMB N/A
  • Industry
  • PWUP Blank Checks
  • ASMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • PWUP Finance
  • ASMB Health Care
  • Exchange
  • PWUP Nasdaq
  • ASMB Nasdaq
  • Market Cap
  • PWUP 87.4M
  • ASMB 83.8M
  • IPO Year
  • PWUP 2022
  • ASMB 2010
  • Fundamental
  • Price
  • PWUP $11.27
  • ASMB $14.30
  • Analyst Decision
  • PWUP
  • ASMB Hold
  • Analyst Count
  • PWUP 0
  • ASMB 1
  • Target Price
  • PWUP N/A
  • ASMB N/A
  • AVG Volume (30 Days)
  • PWUP 237.0
  • ASMB 20.0K
  • Earning Date
  • PWUP 01-01-0001
  • ASMB 08-07-2024
  • Dividend Yield
  • PWUP N/A
  • ASMB N/A
  • EPS Growth
  • PWUP N/A
  • ASMB N/A
  • EPS
  • PWUP 0.18
  • ASMB N/A
  • Revenue
  • PWUP N/A
  • ASMB N/A
  • Revenue This Year
  • PWUP N/A
  • ASMB N/A
  • Revenue Next Year
  • PWUP N/A
  • ASMB $20.00
  • P/E Ratio
  • PWUP $62.50
  • ASMB N/A
  • Revenue Growth
  • PWUP N/A
  • ASMB N/A
  • 52 Week Low
  • PWUP $10.07
  • ASMB $7.68
  • 52 Week High
  • PWUP $13.70
  • ASMB $20.04
  • Technical
  • Relative Strength Index (RSI)
  • PWUP 44.86
  • ASMB 50.51
  • Support Level
  • PWUP $11.26
  • ASMB $13.60
  • Resistance Level
  • PWUP $11.69
  • ASMB $14.42
  • Average True Range (ATR)
  • PWUP 0.00
  • ASMB 0.79
  • MACD
  • PWUP -0.01
  • ASMB -0.05
  • Stochastic Oscillator
  • PWUP 9.52
  • ASMB 60.17

About PWUP PowerUp Acquisition Corp.

PowerUp Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: